Why the study?
Existing approved transcatheter pulmonary valves have limitations and do not cover the entire patient population, necessitating more valve options to improve outcomes with fewer complications.
Does the Myval transcatheter heart valve system safely and effectively treat severe pulmonary regurgitation and conduit dysfunction in patients with congenital heart disease?
Does the Myval transcatheter heart valve system safely and effectively treat severe pulmonary regurgitation and conduit dysfunction in patients with congenital heart disease?
The Myval transcatheter heart valve system appears to be a clinically feasible and effective off-label option for percutaneous pulmonary valve implantation in native right ventricular outflow tracts and conduits.
Answers are grounded in this paper and cite their sources.
Should not yet change PPVI device choice; leaves open whether Myval can safely expand options for large native RVOTs.
The rate of morbidity and mortality related to pulmonary regurgitation and pulmonary stenosis are big concerns after the surgery for CHD. Percutaneous pulmonary valve implantation has been established as a less invasive technique compared to surgery with promising results according to long-term follow-up of the patients. There are only two approved valve options for percutaneous pulmonary valve implantation until now, which are Melody (Medtronic, Minneapolis, Minn, USA) and Sapien (Edwards Lifesciences, Irvine, Ca, USA). Both valves have limitations and do not cover entire patient population. Therefore, the cardiologists need more options to improve outcomes with fewer complications in a such promising area. Herein, we present a case series applying for pulmonary position in conduits and native right ventricular outflow tract of a new transcatheter valve system Myval ® which is designed for transcatheter aortic valve implantation procedures. This is the first patient series in which the use of Myvalv in dysfunctional right ventricular outflow tracts is described, after surgical repair of CHD.
No takes yet. Share an insight, caveat, or question.
A 2021 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: